Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 15, 2011
Tue, June 14, 2011 
ALPHARETTA, Ga.--([ BUSINESS WIRE ])--SANUWAVE Health, Inc. (OTCBB: SNWV) ([ www.sanuwave.com ]), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today reported that the U.S. Patent and Trademark Office (USPTO) issued a reexamination certificate upholding ten amended claims of SANUWAVEa™s U.S. Patent No. 6,080,119 following a third partya™s ex parte reexamination request. This innovative device and method patent describes the Companya™s invention of effective catalyst concentrations to produce optimal medical shock waves.
"We are very pleased that the reexamination proceedings have been brought to a successful conclusion. We believe that the issuance of this reexamination certificate confirms SANUWAVEa™s technological leadership in medical shock wave technology"
The USPTO confirmed that SANUWAVE was entitled to amend the patent claims to the full range of catalyst concentrations disclosed in the a119 patent as a continuing novel innovation in medical shock wave treatment.
"We are very pleased that the reexamination proceedings have been brought to a successful conclusion. We believe that the issuance of this reexamination certificate confirms SANUWAVEa™s technological leadership in medical shock wave technology," said Christopher M. Cashman, President and CEO of SANUWAVE. "This patent recognizes our technology as a novel innovation, allowing us to aggressively defend our intellectual property. The strength of this intellectual property, combined with compelling clinical outcomes and favorable market dynamics, allow us to continually advance our PACE® technology across multiple market verticals, with a near-term focus on wound healing and orthopedics.a
About PACE
PACE, defined as Pulsed Acoustic Cellular Expression, delivers high-energy acoustic pressure waves to produce compressive and tensile stresses on cells and tissue structures to promote angiogenic and positive inflammatory responses, and quickly initiate the healing cascade. This results in revascularization and microcirculatory improvement, including the production of angiogenic growth factors, enhanced new blood vessel formation (angiogenesis), and the subsequent regeneration of tissue such as skin, musculoskeletal and vascular structures. PACE treatment triggers the initiation of an accelerated inflammatory response that speeds wounds into proliferation phases of healing, and subsequently returns a chronic condition to an acute condition to help re-initiate the bodya™s own healing response.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. ([ www.sanuwave.com ]) is an emerging regenerative medicine company focused on the development and commercialization of non-invasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVEa™s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the bodya™s normal healing processes and regeneration. SANUWAVE intends to apply its PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE marked for treatment of the skin and subcutaneous soft tissue and recently completed its highly positive pivotal Phase III, Investigational Device Exemption (IDE) trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron, Evotrona" and orthoPACE® devices in Europe.
Forward-Looking Statements
This press release may contain aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companya™s ability to control.Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Companya™s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Companya™s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Companya™s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
